Viking Therapeutics Just Announced More Positive Results: Time to Buy?
The drugmaker isn’t losing momentum.
Mindfully Curated
The drugmaker isn’t losing momentum.
Etsy is still struggling to grow sales on its e-commerce platform.
Altria has a huge dividend yield, but long-term investors need to look past the alluring yield and focus on the business.
In coordination with Bitcoin Park, ARK is pleased to introduce a monthly conversation with leaders in the Bitcoin space.
When your employer is running the plan, you have to play by its rules.
This stock’s upside is huge, but so is its downside.
The company’s stock is poised to soar very high, in the view of a pundit tracking its fortunes.
The AI boom is just getting started.
What happened to the hype around Vision Pro?
This is a long-term bet, but the time to buy is now.
Despite a remarkable bull run, there’s still an untapped opportunity for investors.
Enterprise Products Partners highlighted how difficult the energy industry environment was in 2023, but it still posted record results.
If your retirement accounts aren’t quite where they should be, here are some ways to fix the problem.
Realty Income is over three times the size of its next-largest competitor, but still has plenty of market opportunity ahead.
IBM’s AI business is one of those overnight success stories that were years in the making. Check out where Big Blue is going next — and how.
Costco knows its customers very well, but Dollar Tree seems like it has forgotten why people shop at its stores.
Home Depot just made its biggest acquisition ever.
This analyst is growing cautious about the company’s prospects in the near term.
Which of these AI-driven automation players is a better buy right now?
Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential.